224 related articles for article (PubMed ID: 34671111)
1. AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome.
Li P; White T; Xie W; Cui W; Peker D; Zeng G; Wang HY; Vagher J; Brown S; Williams M; Kovacsovics T; Patel JL
Leukemia; 2022 Mar; 36(3):664-674. PubMed ID: 34671111
[TBL] [Abstract][Full Text] [Related]
2. Germline DDX41 mutations define a significant entity within adult MDS/AML patients.
Sébert M; Passet M; Raimbault A; Rahmé R; Raffoux E; Sicre de Fontbrune F; Cerrano M; Quentin S; Vasquez N; Da Costa M; Boissel N; Dombret H; Peffault de Latour R; Socié G; Itzykson R; Fenaux P; Soulier J; Adès L; Clappier E
Blood; 2019 Oct; 134(17):1441-1444. PubMed ID: 31484648
[TBL] [Abstract][Full Text] [Related]
3. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
Li P; Brown S; Williams M; White T; Xie W; Cui W; Peker D; Lei L; Kunder CA; Wang HY; Murray SS; Vagher J; Kovacsovics T; Patel JL
Blood; 2022 Aug; 140(7):716-755. PubMed ID: 35671390
[TBL] [Abstract][Full Text] [Related]
4. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.
Alkhateeb HB; Nanaa A; Viswanatha D; Foran JM; Badar T; Sproat L; He R; Nguyen P; Jevremovic D; Salama ME; Greipp P; Gangat N; Tefferi A; Litzow MR; Mangaonkar AA; Shah MV; Patnaik M; Al-Kali A
Blood Adv; 2022 Jan; 6(2):528-532. PubMed ID: 34644397
[TBL] [Abstract][Full Text] [Related]
5. Unique ethnic features of
Choi EJ; Cho YU; Hur EH; Jang S; Kim N; Park HS; Lee JH; Lee KH; Kim SH; Hwang SH; Seo EJ; Park CJ; Lee JH
Haematologica; 2022 Feb; 107(2):510-518. PubMed ID: 33626862
[TBL] [Abstract][Full Text] [Related]
6. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
Makishima H; Saiki R; Nannya Y; Korotev S; Gurnari C; Takeda J; Momozawa Y; Best S; Krishnamurthy P; Yoshizato T; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Nagata Y; Kakiuchi N; Onizuka M; Chiba K; Tanaka H; Kon A; Ochi Y; Nakagawa MM; Okuda R; Mori T; Yoda A; Itonaga H; Miyazaki Y; Sanada M; Ishikawa T; Chiba S; Tsurumi H; Kasahara S; Müller-Tidow C; Takaori-Kondo A; Ohyashiki K; Kiguchi T; Matsuda F; Jansen JH; Polprasert C; Blombery P; Kamatani Y; Miyano S; Malcovati L; Haferlach T; Kubo M; Cazzola M; Kulasekararaj AG; Godley LA; Maciejewski JP; Ogawa S
Blood; 2023 Feb; 141(5):534-549. PubMed ID: 36322930
[TBL] [Abstract][Full Text] [Related]
7. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.
Maierhofer A; Mehta N; Chisholm RA; Hutter S; Baer C; Nadarajah N; Pohlkamp C; Thompson ER; James PA; Kern W; Haferlach C; Meggendorfer M; Haferlach T; Blombery P
Blood Adv; 2023 Dec; 7(23):7346-7357. PubMed ID: 37874914
[TBL] [Abstract][Full Text] [Related]
8. Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.
Badar T; Chlon T
Curr Hematol Malig Rep; 2022 Oct; 17(5):113-120. PubMed ID: 35781188
[TBL] [Abstract][Full Text] [Related]
9. DDX41-related myeloid neoplasia.
Maciejewski JP; Padgett RA; Brown AL; Müller-Tidow C
Semin Hematol; 2017 Apr; 54(2):94-97. PubMed ID: 28637623
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
Duployez N; Largeaud L; Duchmann M; Kim R; Rieunier J; Lambert J; Bidet A; Larcher L; Lemoine J; Delhommeau F; Hirsch P; Fenwarth L; Kosmider O; Decroocq J; Bouvier A; Le Bris Y; Ochmann M; Santagostino A; Adès L; Fenaux P; Thomas X; Micol JB; Gardin C; Itzykson R; Soulier J; Clappier E; Recher C; Preudhomme C; Pigneux A; Dombret H; Delabesse E; Sébert M
Blood; 2022 Aug; 140(7):756-768. PubMed ID: 35443031
[TBL] [Abstract][Full Text] [Related]
11. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Quesada AE; Routbort MJ; DiNardo CD; Bueso-Ramos CE; Kanagal-Shamanna R; Khoury JD; Thakral B; Zuo Z; Yin CC; Loghavi S; Ok CY; Wang SA; Tang Z; Bannon SA; Benton CB; Garcia-Manero G; Kantarjian H; Luthra R; Medeiros LJ; Patel KP
Am J Hematol; 2019 Jul; 94(7):757-766. PubMed ID: 30963592
[TBL] [Abstract][Full Text] [Related]
12. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.
Polprasert C; Schulze I; Sekeres MA; Makishima H; Przychodzen B; Hosono N; Singh J; Padgett RA; Gu X; Phillips JG; Clemente M; Parker Y; Lindner D; Dienes B; Jankowsky E; Saunthararajah Y; Du Y; Oakley K; Nguyen N; Mukherjee S; Pabst C; Godley LA; Churpek JE; Pollyea DA; Krug U; Berdel WE; Klein HU; Dugas M; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Yoshida K; Ogawa S; Müller-Tidow C; Maciejewski JP
Cancer Cell; 2015 May; 27(5):658-70. PubMed ID: 25920683
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular correlates of somatic and germline
Badar T; Nanaa A; Foran JM; Viswanatha D; Al-Kali A; Lasho T; Finke C; Alkhateeb HB; He R; Gangat N; Shah M; Tefferi A; Mangaonkar AA; Litzow MR; Ongie LJ; Chlon T; Ferrer A; Patnaik MM
Haematologica; 2023 Nov; 108(11):3033-3043. PubMed ID: 37199125
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and significance of DDX41 gene variants in the general population.
Cheloor Kovilakam S; Gu M; Dunn WG; Marando L; Barcena C; Nik-Zainal S; Mohorianu I; Kar SP; Fabre MA; Quiros PM; Vassiliou GS
Blood; 2023 Oct; 142(14):1185-1192. PubMed ID: 37506341
[TBL] [Abstract][Full Text] [Related]
15. Myeloid neoplasms with germline DDX41 mutation.
Cheah JJC; Hahn CN; Hiwase DK; Scott HS; Brown AL
Int J Hematol; 2017 Aug; 106(2):163-174. PubMed ID: 28547672
[TBL] [Abstract][Full Text] [Related]
16. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report.
Shin WY; Yoon SY; Park R; Kim JA; Song HH; Bang HI; Won JH; Kim J
BMC Med Genomics; 2022 Mar; 15(1):46. PubMed ID: 35246110
[TBL] [Abstract][Full Text] [Related]
17. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.
Lewinsohn M; Brown AL; Weinel LM; Phung C; Rafidi G; Lee MK; Schreiber AW; Feng J; Babic M; Chong CE; Lee Y; Yong A; Suthers GK; Poplawski N; Altree M; Phillips K; Jaensch L; Fine M; D'Andrea RJ; Lewis ID; Medeiros BC; Pollyea DA; King MC; Walsh T; Keel S; Shimamura A; Godley LA; Hahn CN; Churpek JE; Scott HS
Blood; 2016 Feb; 127(8):1017-23. PubMed ID: 26712909
[TBL] [Abstract][Full Text] [Related]
18. Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
Qu S; Li B; Qin T; Xu Z; Pan L; Hu N; Huang G; Peter Gale R; Xiao Z
Br J Haematol; 2021 Mar; 192(6):1006-1010. PubMed ID: 32307695
[TBL] [Abstract][Full Text] [Related]
19. Novel DDX41 variants in Thai patients with myeloid neoplasms.
Polprasert C; Takeda J; Niparuck P; Rattanathammethee T; Pirunsarn A; Suksusut A; Kobbuaklee S; Wudhikarn K; Lawasut P; Kongkiatkamon S; Chuncharunee S; Songserm K; Phowthongkum P; Bunworasate U; Nannya Y; Yoshida K; Makishima H; Ogawa S; Rojnuckarin P
Int J Hematol; 2020 Feb; 111(2):241-246. PubMed ID: 31713024
[TBL] [Abstract][Full Text] [Related]
20. Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia.
Kadono M; Kanai A; Nagamachi A; Shinriki S; Kawata J; Iwato K; Kyo T; Oshima K; Yokoyama A; Kawamura T; Nagase R; Inoue D; Kitamura T; Inaba T; Ichinohe T; Matsui H
Exp Hematol; 2016 Aug; 44(8):745-754.e4. PubMed ID: 27174803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
